万征;李永乐;
WAN Zheng;LI Yong-le;Department of Cardiology,Tianjin Medical University General Hospital;

• 1:天津医科大学总医院心内科

摘要(Abstract)：

抗凝治疗是血栓栓塞性疾病,尤其是肺栓塞防治的重要措施。华法林作为经典的抗凝药物,从20世纪50年代起用于治疗血栓栓塞性疾病。相比华法林,新型口服抗凝药物(novel oral anticoagulants,NOACs)具有药代动力学稳定、可固定剂量使用、无须频繁监测凝血功能、与药物及食物相互作用少、药物安全性良好等突出优点。NOACs给临床医生带来更多用药选择的同时,也挑战了华法林在抗凝领域的地位。然而目前很多临床情况下,华法林的抗凝价值仍不可替代。
Anticoagulation therapy is an important measure for the treatment and prevention of thromboembolic diseases,especially pulmonary embolism. Warfarin,as a classic anticoagulant drug,has been applied to thromboembolic diseases since the 1950 s. Compared with warfarin,novel oral anticoagulants( NOACs) have the advantages of stable pharmacokinetics,fixed-dose usage,no need for frequent monitoring of coagulation function,less interaction with drugs and foods,and good drug safety. The emergence of NOACs has given clinicians more choice of drugs,and it also challenges warfarin's position in the field of anticoagulation. However,there is no medicine to replace warfarin yet in many clinical scenarios. Warfarin still has the value of its existence.

关键词(KeyWords)： 华法林;新型口服抗凝药物
warfarin;novel oral anticoagulants

Abstract:

Keywords:

基金项目(Foundation):

作者(Authors): 万征;李永乐;
WAN Zheng;LI Yong-le;Department of Cardiology,Tianjin Medical University General Hospital;

参考文献(References)：

• [1]van Walraven C,Hart RG,Singer DE,et al.Oral anticoagu-lants vs aspirin in nonvalvular atrial fibrillation:an individual patient meta-analysis[J].JAMA,2002,288:2441-2448.
• [2]ACTIVE Writing Group of the ACTIVE Investigators,Connolly S,Pogue J,et al.Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events(ACTIVE W):a randomised controlled trial[J].Lancet,2006,367:1903-1912.
• [3]Hart RG,Pearce LA,Aguilar MI.Meta-analysis:antithrombotic therapy toprevent stroke in patients who have nonvalvular atrial fibrillation[J].Ann Intern Med,2007,146:857-867.
• [4]Connolly SJ,Ezekowitz MD,Yusuf S,et al.Dabigatran versus warfarin in patients with atrial fibrillation[J].N Engl J Med,2009,361:1139-1151.
• [5]Patel MR,Mahaffey KW,Garg J,et al.Rivaroxaban versus warfarin in nonvalvular atrial fibrillation[J].N Engl J Med,2011,365:883-891.
• [6]Granger CB,Alexander JH,Mc Murray JJ,et al.Apixaban versus warfarin in patients with atrial fibrillation[J].N Engl J Med,2011,365:981-992.
• [7]Giugliano RP,Ruff CT,Braunwald E,et al.Edoxaban versus warfarin in patients with atrial fibrillation[J].N Engl J Med,2013,369:2093-2104.
• [8]Ruff CT,Giugliano RP,Braunwald E,et al.Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation:a meta-analysis of randomised trials[J].Lancet,2014,383:955-962.
• [9]Kirchhof P,Benussi S,Kotecha D,et al.2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS[J].Europace,2016,18:1609-1678.
• [10]Schulman S,Kakkar AK,Goldhaber SZ,et al.Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis[J].Circulation,2014,129:764-772.
• [11]Hokusai VTEI,Buller HR,Decousus H,et al.Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism[J].N Engl J Med,2013,369:1406-1415.
• [12]Agnelli G,Buller HR,Cohen A,et al.Oral apixaban for the treatment of acute venous thromboembolism[J].N Engl J Med,2013,369:799-808.
• [13]Investigators EP,Buller HR,Prins MH,et al.Oral rivaroxaban for the treatment of symptomatic pulmonary embolism[J].N Engl J Med,2012,366:1287-1297.
• [14]Kearon C,Akl EA,Ornelas J,et al.Antithrombotic Therapy for VTE Disease:CHEST Guideline and Expert Panel Report[J].Chest,2016,149:315-352.
• [15]Eikelboom JW,Connolly SJ,Brueckmann M,et al.Dabigatran versus warfarin in patients with mechanical heart valves[J].N Engl J Med,2013,369:1206-1214.
• [16]Hoffman R,Brenner B.The promise of novel direct oral anticoagulants[J].Best Pract Res Clin Haematol,2012,25:351-360.
• [17]中华医学会心血管病学分会,中国老年学学会心脑血管病专业委员会.华法林抗凝治疗的中国专家共识[J].中华内科杂志,2013:76-82.
• [18]Gallagher AM,Setakis E,Plumb JM,et al.Risks of strokeand mortality associated with suboptimal anticoagulation in atrial fibrillation patients[J].Thromb Haemost,2011,106:968-977.